Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
17α Hydroxyprogesterone Caproate for Preterm Labor Prevention
NCT01317225Phase 3
Key facts
- Status
- Unknown
- Start
- Jun 2011
- Primary completion
- Jul 2015
- Countries
- 1
- Sponsor
- Hospital Santo Tomás
- Modality
- Small Molecules
- Conditions
- preterm birth
01
Overview
Phase 3, randomised, double-blind trial of hydroxyprogesterone caproate in preterm birth, sponsored by Hospital Santo Tomás. Primary endpoint: Incidence of preterm birth before 37 weeks of gestation at 18 months. Status: unknown.
02
Design
- Study design
- RandomizedDouble-blind
03
Endpoints
Primary
Incidence of preterm birth before 37 weeks of gestation
Secondary
Incidence of preterm birth before 35 weeks of pregnancy
Beyond the preview
Go deeper on NCT01317225.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01317225.